

Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Clinical Roundup


NCI Trials


NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Why both somatic and germline genomic profiling are essential for precision oncology















